Payment is a benefit and why it matters for pediatric trials
Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. F...
| 主要作者: | |
|---|---|
| 格式: | 電子 Article |
| 語言: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | 載入...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| 出版: |
Wiley-Blackwell
2022
|
| In: |
Bioethics
Year: 2022, 卷: 36, 發布: 7, Pages: 757-764 |
| IxTheo Classification: | NCH Medical ethics NCJ Ethics of science |
| Further subjects: | B
benefit analyses / risk
B research ethics B children and families |
| 在線閱讀: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
| 總結: | Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. First, I explain why the practical implications of these arguments for studies enrolling competent adults are less than fully clear. Second, I explain why the practical implication for trials enrolling children are clear and significant. I argue that we should be comfortable paying children to compensate them for undergoing research risks. I propose we do so by putting money into accounts that the child gains access to upon attaining majority. |
|---|---|
| ISSN: | 1467-8519 |
| Contains: | Enthalten in: Bioethics
|
| Persistent identifiers: | DOI: 10.1111/bioe.13011 |